English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We have investigated PhIP-induced mutagenicity in various tissues (kidney, liver, large and small intestine) using a transgenic mouse model (MutaMouse). In addition to tissue specific mutagenesis, we measured the binding of [14C]PhIP to MutaMouse mice blood proteins (haemoglobin and albumin), to obtain a quantitative estimate of carcinogen exposure and activation and their relationship to mutagenesis. Short-term (4 days) treatment of MutaMouse mice with [14C]PhIP by oral gavage resulted in the dose-dependent accumulation of radiolabelled material bound to haemoglobin and serum albumin. PhIP, at the highest dose (20 mg/kg), caused a 5.9-fold increase in the mutation frequency in the large intestine, a 4.2-fold increase in the mutation frequency in the small intestine but only a marginal 1.6-fold increase in the liver. However, there was no significant increase in mutations in the kidney at this dose. In contrast, there were no significant differences in any of these tissues between the vehicle control and the two lower doses (2.0 and 0.2 mg/kg respectively). These results are discussed in relationship to those previously reported for PhIP at the Dlb-1 locus.

Organ distinctive mutagenicity in MutaTMMouse after short-term exposure to PhIP

Organ distinctive mutagenicity in Muta^TMMouse after short-term exposure to PhIP